Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Aurobindo Pharma Receives Tentative FDA Approval to Produce Chewable Tablets of Generic Antiretroviral Didanosine for PEPFAR

July 13, 2006

FDA has granted tentative approval to Indian drug manufacturer Aurobindo Pharma to produce a chewable tablet form of the antiretroviral drug didanosine, Iris.com reports (Iris.com, 7/12). Didanosine is a generic version of Bristol-Myers Squibb's VIDEX, which was FDA-approved in December 2004. The drug is used in combination with other antiretrovirals for the treatment of HIV-1 infection (Kaiser Daily HIV/AIDS Report, 12/6/04). The tentative approval allows Aurobindo to produce the drug in strengths of 100mg, 150mg and 200mg. This is the first time FDA has tentatively approved a generic version of didanosine in chewable tablet form (Iris.com, 7/12). The tentative approval designation means the generic drug meets FDA safety and efficacy standards but cannot be sold in the U.S. because of existing patents or exclusivity agreements, although it can be used by relief organizations outside the U.S. under the President's Emergency Plan for AIDS Relief (Kaiser Daily HIV/AIDS Report, 7/3).

Back to other news for July 13, 2006


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2006 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement